CUE [NASD]
Cue Biopharma, Inc.
Index- P/E- EPS (ttm)-1.44 Insider Own3.20% Shs Outstand32.64M Perf Week-18.33%
Market Cap88.10M Forward P/E- EPS next Y-1.79 Insider Trans- Shs Float29.35M Perf Month-33.78%
Income-45.90M PEG- EPS next Q-0.44 Inst Own51.00% Short Float12.21% Perf Quarter-49.80%
Sales14.40M P/S6.12 EPS this Y9.60% Inst Trans8.11% Short Ratio6.83 Perf Half Y-78.51%
Book/sh1.98 P/B1.24 EPS next Y-8.70% ROA-53.60% Target Price24.17 Perf Year-80.02%
Cash/sh- P/C- EPS next 5Y- ROE-68.90% 52W Range2.45 - 18.42 Perf YTD-78.34%
Dividend- P/FCF- EPS past 5Y-25.10% ROI-67.50% 52W High-86.70% Beta1.74
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low-0.20% ATR0.33
Employees57 Current Ratio6.70 Sales Q/Q-37.50% Oper. Margin- RSI (14)32.46 Volatility12.20% 9.85%
OptionableYes Debt/Eq0.15 EPS Q/Q-6.30% Profit Margin- Rel Volume0.62 Prev Close2.49
ShortableYes LT Debt/Eq0.15 Earnings- Payout- Avg Volume524.87K Price2.45
Recom1.50 SMA20-24.13% SMA50-32.21% SMA200-70.70% Volume323,715 Change-1.61%
Jan-13-22Initiated H.C. Wainwright Buy $20
Jan-03-22Initiated Craig Hallum Buy $28
Nov-24-20Initiated Berenberg Buy $30
Apr-09-20Initiated Stifel Buy $21
Jan-28-20Initiated BTIG Research Buy $26
Jan-22-20Initiated JMP Securities Mkt Outperform $22
Jun-27-22 10:49AM  
Jun-13-22 08:00AM  
Jun-02-22 06:56AM  
Jun-01-22 08:00AM  
May-26-22 05:00PM  
May-11-22 08:00AM  
May-10-22 04:30PM  
11:23AM  
May-06-22 08:25AM  
May-05-22 09:45AM  
May-04-22 06:25PM  
Apr-05-22 09:09PM  
Apr-04-22 09:06AM  
Mar-23-22 09:25AM  
Mar-19-22 08:19AM  
Mar-10-22 08:00AM  
Mar-09-22 05:15PM  
Mar-02-22 08:00AM  
Feb-24-22 05:40PM  
Feb-23-22 09:00PM  
Feb-15-22 08:22AM  
08:00AM  
Feb-13-22 06:28PM  
08:46AM  
Jan-27-22 05:24AM  
Jan-26-22 04:01PM  
Jan-20-22 08:00AM  
Jan-05-22 08:00AM  
Dec-30-21 05:49AM  
Dec-15-21 08:00AM  
Dec-06-21 08:00AM  
Nov-22-21 08:00AM  
Nov-15-21 05:42AM  
Nov-12-21 08:00AM  
Nov-10-21 08:00AM  
Nov-09-21 03:00PM  
Oct-21-21 12:00PM  
Oct-04-21 08:00AM  
Oct-01-21 06:22AM  
Sep-28-21 08:00AM  
Sep-21-21 08:00AM  
Sep-09-21 08:00AM  
Aug-23-21 07:04AM  
Aug-17-21 04:01PM  
Aug-10-21 08:00AM  
Aug-03-21 08:00AM  
Jul-30-21 03:00PM  
Jun-14-21 08:00AM  
Jun-10-21 08:00AM  
Jun-03-21 08:30AM  
May-26-21 08:00AM  
May-24-21 02:18AM  
May-17-21 04:01PM  
May-11-21 08:42AM  
May-10-21 01:14PM  
10:00AM  
08:00AM  
May-06-21 08:00AM  
Apr-09-21 02:14AM  
Mar-16-21 04:01PM  
Mar-15-21 08:00AM  
Mar-09-21 08:00AM  
Mar-01-21 08:00AM  
Feb-25-21 08:00AM  
Feb-23-21 12:17AM  
Feb-22-21 08:00AM  
Feb-17-21 08:00AM  
Feb-08-21 08:00AM  
Jan-29-21 03:34PM  
Jan-09-21 02:27AM  
Dec-15-20 10:30PM  
Dec-07-20 08:53AM  
Nov-25-20 12:02AM  
Nov-24-20 09:51AM  
Nov-23-20 08:00AM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 08:00AM  
Nov-03-20 06:25AM  
Oct-19-20 08:00AM  
Oct-14-20 11:30AM  
Sep-17-20 08:00AM  
Sep-15-20 08:00AM  
Sep-10-20 08:36AM  
Sep-04-20 10:07AM  
Sep-03-20 08:00AM  
Aug-31-20 04:01PM  
Aug-24-20 08:00AM  
Aug-17-20 08:00AM  
Aug-06-20 12:30PM  
Jul-28-20 08:00AM  
Jul-08-20 08:00AM  
Jul-06-20 02:36PM  
Jun-27-20 09:12PM  
Jun-15-20 08:00AM  
May-28-20 08:00AM  
May-20-20 09:01PM  
May-19-20 10:00PM  
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morich FrankDirectorMay 27Buy3.7528,000105,00028,000May 31 04:06 PM
Fletcher Aaron G.L.DirectorMay 24Buy3.3455,000183,700940,000May 25 09:09 AM
Fletcher Aaron G.L.DirectorMay 23Buy3.52150,000528,000885,000May 25 09:09 AM
Fletcher Aaron G.L.DirectorMar 31Buy4.76735,0003,498,600735,000Apr 04 05:28 PM
Kiener Peter ADirectorNov 16Option Exercise2.861,3613,8921,361Nov 17 05:00 PM
Kiener Peter ADirectorNov 16Sale18.021,36124,5250Nov 17 05:00 PM
Suri AnishPresident and CSONov 15Option Exercise8.268,00066,080102,038Nov 17 05:00 PM
Kiener Peter ADirectorNov 15Option Exercise2.8618,81553,81118,815Nov 17 05:00 PM
Kiener Peter ADirectorNov 15Sale17.9218,815337,1650Nov 17 05:00 PM
Suri AnishPresident and CSONov 15Sale18.058,000144,40094,038Nov 17 05:00 PM
Suri AnishPresident and CSONov 11Option Exercise6.4220,000128,400114,038Nov 15 05:00 PM
Suri AnishPresident and CSONov 11Sale15.0720,000301,35494,038Nov 15 05:00 PM
Millar Kerri-AnnCHIEF FINANCIAL OFFICEROct 01Option Exercise7.501,2519,38211,723Oct 05 07:21 PM
Millar Kerri-AnnCHIEF FINANCIAL OFFICEROct 01Sale14.211,25117,78310,472Oct 05 07:21 PM
PASSERI DANIEL RCHIEF EXECUTIVE OFFICERSep 24Buy14.723,40050,05155,377Sep 27 04:30 PM
Suri AnishPRESIDENT AND CSOSep 23Option Exercise6.4220,000128,40094,838Sep 27 04:30 PM
Suri AnishPRESIDENT AND CSOSep 23Sale15.2320,000304,64674,838Sep 27 04:30 PM
Millar Kerri-AnnCHIEF FINANCIAL OFFICERAug 23Option Exercise0.006,667012,433Oct 05 07:21 PM